<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) occurs less frequently with the <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogs than with DNA-damaging agents such as alkylators or <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>In a chemoimmunotherapy trial conducted between 1997 and 2003 in patients with stage IV indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 202 patients were treated and 8 have developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> between 1 and 5 years after therapy, including 4 who received only fludarabine, <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi>, and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> (FND) for 6 to 8 courses, with or without rituximab, followed by interferon alpha (IFN-alpha) </plain></SENT>
<SENT sid="2" pm="."><plain>Complex cytogenetic abnormalities were present in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Abnormalities of chromosome 7 were present in 6 of the 8 patients, 3 of whom received only FND +/- rituximab and IFN-alpha </plain></SENT>
<SENT sid="4" pm="."><plain>The abnormalities of chromosome 7 were <z:mp ids='MP_0004026'>monosomy</z:mp> 7 in 4 patients (1 of which had add 7p in the remaining chromosome); 1 del 7q; and 1 der 7 </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with features classically associated with DNA-damaging agents can occur following therapy with FND, with or without rituximab, and IFN-alpha </plain></SENT>
</text></document>